Accessibility Menu
Rallybio Stock Quote

Rallybio (NASDAQ: RLYB)

$0.74
(-0.3%)
-0.00
Price as of December 12, 2025, 3:57 p.m. ET

KEY DATA POINTS

Current Price
$0.73
Daily Change
(-0.3%) $0.00
Day's Range
$0.72 - $0.74
Previous Close
$0.73
Open
$0.74
Beta
N/A
Volume
40,537
Average Volume
255,583
Market Cap
$31M
Market Cap / Employee
$0.73M
52wk Range
$0.22 - $1.08
Revenue
N/A
Gross Margin
0.82%
Dividend Yield
N/A
EPS
-$0.32
CAPs Rating
N/A
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Rallybio Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
RLYB-34.64%N/AN/A-95%
S&P+12.83%+86.37%+13.24%+54%
Advertisement

Rallybio Company Info

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

News & Analysis

No results found

No news articles found for Rallybio.

Financial Health

General

Q3 2025YOY Change
Revenue$212.00K-29.1%
Gross Profit$177.00K-33.7%
Gross Margin83.49%-5.8%
Market Cap$20.85M-57.0%
Market Cap / Employee$868.81K0.0%
Employees240.0%
Net Income$16.02M239.7%
EBITDA-$5,190.00K56.9%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$32.12M26.9%
Inventory00.0%

Liabilities

Q3 2025YOY Change
Long Term Debt$108.00K0.0%
Short Term Debt$90.00K-60.9%

Ratios

Q3 2025YOY Change
Return On Assets-19.32%43.8%
Return On Invested Capital-49.86%2.1%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$6,550.00K51.6%
Operating Free Cash Flow-$6,550.00K51.6%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book0.560.440.260.45-25.35%
Price to Sales67.4134.5619.9233.36-61.76%
Price to Tangible Book Value0.560.440.260.45-25.35%
Enterprise Value to EBITDA1.942.603.677.06273.65%
Return on Equity-68.8%-67.3%-66.1%-21.2%-69.27%
Total Debt$154.00K$116.00K$58.00K$198.00K-13.91%

No results found

No podcast episodes available.

No results found

No transcripts available.

Advertisement

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.